• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Renal mass biopsies more cost-effective, prevent unnecessary procedures

Article

The use of renal mass biopsy to guide treatment decisions for small renal tumors is cost-effective relative to direct surgery, and can spare many patients unnecessary surgical procedures, according to Massachusetts General Hospital researchers.

The use of renal mass biopsy to guide treatment decisions for small renal tumors is cost-effective relative to direct surgery, and can spare many patients unnecessary surgical procedures, according to Massachusetts General Hospital researchers.

Most small renal masses are detected incidentally in imaging and their current treatment is direct surgery, said lead researcher Dr. Pari Pandharipande, a radiologist in the abdominal imaging and interventional radiology department at MGH. Many small renal masses, however, are benign-or indolent if they are malignant-and so less invasive management strategies should be considered, she said during a presentation at the RSNA meeting.

After constructing a decision-analytic Markov model, the researchers determined surgery was about $3500 more expensive than biopsy and resulted in a comparable minimally lower life expectancy. Biopsy therefore dominated surgery from a cost-effectiveness perspective.

The researchers assumed a biopsy sensitivity of 90% and specificity of 100%. The researchers also assumed a postsurgery mortality rate of 1.6%. Among imaging-detected masses, 77% were assumed to reflect renal cell carcinoma.

Biopsy did not dominate surgery under some conditions, for example, when sensitivity was lower than 78%, when surgical mortality was less than 1%, and when prevalence of renal cancer was greater than 87%.

The researchers used a competing-choices cost-effectiveness analysis to compare biopsy with surgery. If one strategy had a lower life expectancy and a higher cost than another, it was considered dominated. If not, an incremental cost-effectiveness ratio was computed and strategy preference was assessed based on an assumed $75,000 per quality adjusted life year societal willingness-to-pay threshold. The long-term outcomes of life expectancy and lifetime costs after biopsy and surgery were estimated by using a decision-analytic Markov model. The cohort in the base-case analysis was 65-year-old men with incidental renal masses.

All patients started with small incidental renal masses and underwent either surgery or biopsy. Patients receiving biopsy could have a true or false positive or negative result. Patients with negative biopsy results underwent CT surveillance for up to five years. Patients with positive and nondiagnostic biopsy specimens underwent direct surgery.   

This story has been updated to better reflect Dr. Pandharipande's research.
 

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.